2 weeks Ago By ABMN Staff
Quest Partners LLC lifted its holdings in shares of Replimune Group, Inc. ( NASDAQ:REPL – Free Report ) by 30.4% in the 2nd quarter, Holdings Channel reports.
The institutional investor owned 13,510 shares of the company’s stock after acquiring an additional 3,150 shares during the period. Quest Partners LLC’s holdings in Replimune Group were worth $122,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds have also modified their holdings of REPL.
Acadian Asset Management LLC acquired a new position in shares of Replimune Group in the 1st quarter valued at $927,000. BNP Paribas Financial Markets boosted its holdings in Replimune Group by 517.9% during the fourth quarter.
BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock worth $1,654,000 after buying an additional 164,490 shares during the last quarter. Clearbridge Investments LLC acquired a new position in shares of Replimune Group during the 4th quarter worth about $2,282,000. Jacobs Levy Equity Management Inc.
bought a new stake in shares of Replimune Group in the 1st quarter valued at about $1,088,000. Finally, Rafferty Asset Management LLC raised its position in shares of Replimune Group by 148.1% in the 4th quarter.
Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after acquiring an additional 276,596 shares during the period. 92.53% of the stock is owned by institutional investors.
Replimune Group Stock Down 6.0 % REPL stock opened at $10.46 on Tuesday.
The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.
46. The stock has a market capitalization of $714.63 million, a P/E ratio of -3.
23 and a beta of 1.22. Replimune Group, Inc.
has a fifty-two week low of $4.92 and a fifty-two week high of $18.12.
The business has a 50-day moving average of $10.15 and a 200-day moving average of $8.37.
Wall Street Analysts Forecast Growth Several brokerages have commented on REPL. Wedbush reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a research note on Thursday, June 6th.
Barclays upped their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th.
Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock.
JPMorgan Chase & Co. lowered their price target on Replimune Group from $17.00 to $14.
00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company.
Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus target price of $16.20.
Get Our Latest Report on REPL Insider Activity at Replimune Group In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.
84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26.
The transaction was disclosed in a document filed with the SEC, which is available at this link . 20.60% of the stock is owned by insiders.
About Replimune Group ( Free Report ) Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. ( NASDAQ:REPL – Free Report ).
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter ..
